Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 08:30 ET | Source: Journey Medical Corporation

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company...
March 31, 2026 16:05 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205...
March 30, 2026 16:05 ET | Source: Fortress Biotech, Inc.

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of...
March 25, 2026 16:01 ET | Source: Journey Medical Corporation

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 ...
March 18, 2026 08:30 ET | Source: Journey Medical Corporation

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on...
February 23, 2026 09:24 ET | Source: Fortress Biotech, Inc.

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...
February 23, 2026 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...
February 23, 2026 08:00 ET | Source: Avenue Therapeutics

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE...
January 13, 2026 07:45 ET | Source: Fortress Biotech, Inc.

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129...
December 15, 2025 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S....